リウマチ病セミナー　XXII　2011

出版社： 永井書店
著者：
発行日： 2011-12-20
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784815918934
シリーズ： リウマチ病セミナー
電子書籍版： 2011-12-20 （初版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

9,020 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,510 円(税込)

購入する

商品紹介

リウマチ学のいまを知らせる好著。本セミナーは，1990年以来毎年発行されて，今回で22冊目。内容は，リウマチ病の捉え方に大きく影響する新しい知見とそれに基づく新しい考え方。リウマトロジーの醍醐味を教えてくれるリウマチ病研究の歴史。そして，今やリウマチ学の最大のテーマである骨粗鬆症の最新知見。多彩で新しい薬剤のレビュー，大きく進歩する手術技術などを取り上げる。常に本領域の水先案内人として，最新の研究成果・治療データを提供してきた。多彩で日進月歩の進展をみせるリウマチ学を一流の研究者たちが思う存分成果を披露している。

目次

  • リウマチ病セミナー　XXII　2011

    ―目次―

    炎症リウマチ
    　2010ACR/EULARの関節リウマチ分類基準　
    　小児の炎症性斜頚
    　自己免疫性甲状腺炎のリウマチ症状　
    　乾癬性関節炎と骨融解　
    　IgG4関連疾患　
    　Behet病2011　
    　Spondyloarthritisの有病率(日本)　
    　RAの発症と煙草：再訪　

    骨関節，脊椎，神経
    　膝関節OAと半月板　
    　Femoroacetabular　impingement　(FAI)の病態と治療　
    　Enthesisの解剖とenthesopathy　
    　仙腸関節の痛みとその診断　
    　脊椎後弯の臨床再訪
    　　−頸椎後彎（首垂れ症）：“隠れ首垂れ症” を探そう−
    　空手とスポーツ障害　　

    燐・カルシウム代謝
    　いつまでビスフォスフォネート薬を使い続けるのか？　

    検査，評価
    　リウマチ病における睡眠検査の意義　　
    　抗シトルリン蛋白抗体2010　　
    　IL23はSpAの新しいマーカーとなるか?　

    生物学的反応
    　慢性疼痛とケモカイン　
    　骨組織の生体ライブイメージング　　

    治療と副作用
    　生物学的製剤からの離脱　　
    　RA患者での免疫抑制剤・生物学的製剤投与による
    　　ウイルス感染への影響　　
    　血管炎に対するＢ細胞標的治療　　
    　SLE治療におけるセルセプトの位置　　
    　クローン病2010−生物学的製剤で変わったクローン病の治療−
    　類骨骨腫のラジオ波焼灼術　　
    　リウマチの足、足関節に対する装具療法　　

    手　　　術
    　人工膝関節置換術の最新情報−動態解析の観点から−　
    　骨粗鬆症性椎体骨折に対する椎体形成術−再訪−　
    　手首の骨折−橈骨遠位端骨折を中心に−

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

炎症リウマチ

P.5 掲載の参考文献
1) Aletaha D, Neogi T, Silman AJ, et al.2010 rheumatoid arthritis classification criteia An american collage of rheumatology/European league against rheumatism collaborative initiateve. Arthritis Rheum 2010; 62:2569-2581.
 
2) Alves C, Luime JJ, van Zeben D, et al. Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid arthritis and two dagnostic algorithms in an early arthritis clinic (REACH). Ann Rheum Dis 2010; 70:1645-1647,
 
3) van der Linden MP, Knevel R, Huizinga TW, et al. Classiffication of rheumatoid arthritis:comparison of the 1987 American college of rheumatology criteria and the 2010 An american collage of rheumatology/European league against rheumatism criteria. Arthritis Rheum 2011; 63:37-42.
 
4) Kaneko Y, Kuwana M, Kameda H, et al. Sensitivity and specificity of 2010 rheumatoid arthritis classification criteia. Rheumatology (Oxford) 2011; 50:1268-1274.
 
5) Bristsemmer K, Ursum J, Gerritsen M, et al. Vallidation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis:slight improvement over the 1987 ACR criteria. Ann Rheum Dis 2011; 70:1468-1470.
PubMed
6) de Hair MJH, Lehmann KA, van der Sande MG, et al. The clinical picture of rheumatoid arthritis according to the 2010 ACR/EULAR criteria:Is this still the same disease? Arthritis Rheum 2011Sep 14 [Epub ahead of print]
 
7) Varache S, Cornec D, Morvan J, et al. Diagnostic accuracy of 2010 ACR/EULAR 2010 criteria for rheumatoid arthritis in a 2-year cohort. J Rheumatol 2011; 38:1250-257.
 
8) Cader MZ, Filer A, Hazlehurst J, et al. Performance of the 2010 ACR/EULAR 2010 criteria for rheumatoid arthritis:comparison with 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 2011:70:949-955.
 
9) Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005; 52:3433-3438
PubMed
P.13 掲載の参考文献
1) Pharisa C, Lutz N, Roback MG et al.Neck complaints in the pediatric emergency department:a consecutive case series of 170 children. Pediatr Emerg Care 2009; 25:823-826.
PubMed
2) Bredenkamp JK, Maceri DR. Inflammatory torticollis in children. Arch Otolaryngol Head Neck Surg 1990; 116:310-313.
PubMed
3) Hicazi A, Acaroglu E, Alanay A et al. Atlantoaxial rotatory fixation-subluxation revisited:a computed tomographic analysis of acute torticollis in pediatric patients. Spine 2002; 27:2771-2775.
PubMed
4) Fielding JW, Hawkins RJ. Atlanto-axial rotatory fixation. J Bone Joint Surg (Am) 1977; 59-A:37-44.
PubMed
5) Mezue WC, Taha ZM, Bashir EM. Fever and acquired torticollis in hospitalized children. J Laryngol Otol 2002; 116:280-284.
PubMed
6) Grisel P. Enucleation de l'atlas et torticolis naso-pharyngien. Presse Med 1930; 38:50-53.
 
7) Kawabe N, Hirotani H, Tanaka O. Pathomechanism of atlantoaxial rotatory fixation in children. J Pediatr Orthop 1989; 9:569-574.
 
8) Mercer S, Bogduk N. Intra-articular inclusions of the cervical synovial joints. Br J Rheumatol 1993:32:703-710.
 
9) Gubin AV, Ulrich EV, Taschilkin AI et al. Etiology of child acute stiff neck. Spine 2009:34:1906-1909.
PubMed
10) Maige J, Mutschler C, Doursounian L. Acute torticollis in an adolescent. Spine 2003; 28:E13-E15.
 
11) Hirsch C, Schajowicz F, Galante J. Structural changes in the cervical spine. A study of autopsy specimens in different age groups. Acta Orthop Scand Suppl 109 Munksgaard Copenhagen 1967.
 
12) Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 1971; 30:213-223.
PubMed
13) 緒方正雄, 福田眞輔, 勝浦章知.リウマチ性頸椎椎間板炎の組織学的検討.日関外誌1991; 10:115-124
 
P.18 掲載の参考文献
1) 中島亜矢子.自己免疫性疾患.臨床と研究2005:82:1319-1322.
 
2) 赤水尚史.甲状腺と自己免疫異常.綜合臨牀2009; 58:1506-1509.
 
3) 日本甲状腺学会.バセドウ病の診断ガイドライン.2008.
 
4) 日本甲状腺学会.慢性甲状腺炎 (橋本病) の診断ガイドライン.2008.
 
5) 日本甲状腺学会.甲状腺機能低下症の診断ガイドライン.2008.
 
6) Boelaert K, Newby PR, Simmond MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010; 123:183. E1-9.
 
7) Lazurova I, Benhatchi K, Rovesky J, et al. Autoimmune thyroid disease and autoimmune rheumatic disorders:a two-sided analysis. Ann N Y Acad 2009:1173:211-216.
 
8) Appenzeller S, Pallone AT, Natalin RA, et al. Prevalence of thyroid dysfunction in systemic lupus erythematosus. J Clin Rheumatol 2009:15:117-119.
PubMed
P.25 掲載の参考文献
1) Elkayam O. Psoriatic arthritis:interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Reumatol 2000; 19:301-305.
 
2) Shbeeb M. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Reumatol 2000; 27:1247-1250.
 
3) Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3:55-78.
PubMed
4) Bennet RM. Psoriatic arthritis. Arthritis and allied conditions 1979:645.
 
5) Gladman DD, Shuckett R, Russel ML, et al. Psoriatic arthritis:an analysis of 220 patients.Q J Med 1987; 238:127-141.
 
6) Vasey F, Espinoza LR. Psoriatic arthropathy. Spondyloarthropathies 1984:151-185.
 
7) Dougados M, van der Linden S, Juhlin R, et al. European Spondylarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991; 34:1218-1227.
 
8) McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis:a unified concept twenty years on. Arthritis Rheum 1999; 42:1080-1086.
PubMed
9) Fournie B, Crognier L, Arnaud C, et al. Proposed classification criteria of psoriatic arthritis:a preliminary study in 260 patients. Rev Rheum Engl Ed 1999; 66:446-456.
 
10) Taylor W, Gladmann D, Helliwell P, et al. Classification criteria for psoriatic arthritis. Arthritis Rheum 2006:54:2665-2673.
 
11) Ritchilin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-α-and RANKL-mediated osteoclastgenesis and bone resorption in psoriatic arthritis. The J of Clin Investigation 2003; 111:821-831.
 
12) 亀田秀人, 奥山あゆみ, 関口直哉.乾癬性関節炎に対するTNF阻害薬の効果.リウマチ科2006; 35:397-401.
 
13) 谷口敦夫.乾癬性関節炎の病態と治療-生物学的製剤が効くのか-.臨床皮膚科学2008; 62:42-45.
 
P.44 掲載の参考文献
1) Comings DE, Skubi KB, Eyes JV, et al. Familial multifocal fibrosclerosis. Findings suggesting that retroperitoneal fibrosis, mediastinal fibrosis, sclerosing cholangitis, Riedel's thyroiditis, and pseudotumor of the orbit may be different manifestations of a single disease. Annals of Internal Medicine 1967; 166:884-892.
 
2) Mikulicz J.Uber Eine Eigenartige Symmetrishe Erkrankung Der Tranen Und Mundspeicheldrusen. Stuttgart:Beitrz. Chir. Fesrschr. F. Theodor Billroth 1892:610-630. In German.
 
3) Sarles H, et al. Chronic inflammatory sclerosis of the pancreas-an autonomous pancreatic disease? Am J Dig Dis 1961; 6:688-698.
PubMed
4) Nakano S, Takeda I, Kitanura K , et al. Vanishing tumor of the abdomen in patient with Sjoegren's syndrome. Digestive Disease 1978:23:75-79 (Supplement).
 
5) Kawaguchi K, Koike M, Tsuruta K, et al.Lymphoplasmacyticsclerosing pancreatitis with cholangitis:a variant of primary sclerosing cholangitis extensively involving pancreas.Hum Pathol 1991:22:387-395.
PubMed
6) Toki F, Kozu T, Oi I, et al. An unusual type of chronic pancreatitis showing di-use irregular narrowing of the entire main pancreatic duct on ERCP-A report of four cases[abstract. Endoscopy 1992; 24:640.
 
7) Yoshida K, Toki F, Takeuchi T et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995; 40:1561-1568.
PubMed
8) Hamano H, Kawa S, Horiuchi A, et al.High serum IgG4 concentrations in patients with sclerosing pancreatitis.N Engl J Med 2001; 344:732-738.
PubMed
9) Hamano H, Kawa S, Ochi Y, et al.Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis.Lancet 2002; 359:1403-1404.
PubMed
10) Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune diseas. J Gastroenterol 2003; 38:982-984.
 
11) Sjogren H:Zur Kenntnis der Keratoconjunctivitis Sicca. Acta Ophthalmol 1933; Suppl II:1-151.
 
12) Sjogren H:A new conception of keratoconjunctivitis sicca. Sydney:Australasian Medical Publishing Company; 1943 (translated by Hamilton JB).
 
13) Morgan WS, Castleman B. A clinicopathologic study of Mikulicz's disease. Am J Pathol 1953; 29:471-503.
PubMed
14) Yamamoto M, Takahashi H, Ohara M, et al.new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Mod Rheumatol 2006; 16:335-340.
PubMed
15) Masaki Y, Dong LKurose N, et al. Proposal for a new clinical entity, IgG4-positive multi-organ lymphoproliferative syndrome:Analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009:68:1310-1315.
 
16) 八田和大.シェーグレン症候群とミクリッツ病.七川歡次編.リウマチ病セミナーXIX.大阪:永井書店:2008:1-9.
 
17) Inoue D, Zen Y, Abo H, et al. Immunoglobulin G4-related lung disease:CT findings with pathologic correlations. Radiology 2009; 251:260-270.
PubMed
18) Zen Y, Inoue D, Kitao A. IgG4-related Lung and Pleural Disease:A Clinicopathologic Study of 21 Cases. Am J Surg Pathol 2009; 33:1886-1893.
PubMed
19) Yamashita K, Haga H, KobashiY, et al.Lung involvement in IgG4-related lymphoplasmacyticvasculitis and interstitial fibrosis:report of 3 cases and review of the literature. Am J SurgPathol 2008; 32:1620-1626.
 
20) Saeki T, Saito A, Yamazaki H, et al. Tubulointerstitial nephritis associated with IgG4-related systemic disease. Clin Exp Nephrol 2007; 11:168-173,
PubMed
21) Saeki T, Nishi S, Imai N, Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney International 2010; 78:1016-1023.
PubMed
22) Imai IH, Imai H, Hamai K, Komatsuda, et al. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis Kidney Internationa 1997; 51:270-276.
 
23) Zen Y, Harada K, Sasaki M. IgG4-related Sclerosing Cholangitis With and Without Hepatic Inflammatory Pseudotumor, and Sclerosing Pancreatitis-associated Sclerosing Cholangitis Do They Belong to a Spectrum of Sclerosing Pancreatitis?Am J SurgPathol 2004:28:1193-1203.
 
24) 八田和大.後腹膜線維症について.七川歡次編.リウマチ病セミナーXVIII, 大阪:永井書店; 2007:102-117.
 
25) Matsumoto Y, Kasashima S, Kawashima A, et al. A case of multiple immunoglobulin G4-related periarteritis:a tumorous lesion of the coronary artery and abdominal aortic aneurysm.Hum Pathol 2008:39:975-980.
PubMed
26) Sato Y, Kojima M, Takata K, et al. Systemic IgG4-related lymphadenopathy:a clinical and pathologic comparison to multicentricCastleman's disease. Mod Pathol 2009; 22:589-599.
 
27) Sato Y, Takata K, Ichimura K et al. IgG4-producing marginal zone B-cell lymphoma. Int J Hematol 2008; 88:428-433.
PubMed
28) Zen Y, Fujii T, Harada K, et al. Th2 and Regulatory Immune Reactions Are Increased in Immunoglobin G4-Related Sclerosing Pancreatitis and Cholangitis.Hepatology 2007; 45:1538-1546.
PubMed
29) Sato Y, Notohara K, Kojima M, et al. IgG4-related disease:Historical overview and pathology of hematological disorders. Pathology International 2010:60:247-258.
PubMed
P.54 掲載の参考文献
1) 石ヶ坪良明 (研究代表者).ベーチェット病に関する調査研究 平成20～22年度総括・分担研究報告書.2011:43-89.
 
2) Mizuki N, Meguro A, Ota M, et al.Genome-wide association studies identify IL-23R-IL 12RB2 and IL 10 as Behget's disease.Nat Genet 2010; 42:703-706.
 
3) 石ヶ坪良明 (研究代表者).腸管ベーチェット病診療ガイドライン平成21年度案～コンセンサス・ステートメントに基づく.ベーチェット病に関する調査研究平成20～22年度総括・分担研究報告書2011:231-234.
 
4) Deal watch:XOMA and Servier to develop anti-1βantibody for inflammatory disease.NatRes Drug Discov 2011; 10:166.
 
5) 廣畑俊成, 菊池弘敏, 桑名正隆ら.神経ベーチェット病の診断予備基準.ベーチェット病に関する調査研 究平成20～22年度総括・分担研究報告書2011:239.
 
6) 水木信久, 渋谷悦子, 目黒 明ら.ベーチェット病眼病変診療ガイドライン.ベーチェット病に関する調査研究平成20～22年度総括・分担研究報告書.2011:197-226.
 
7) A Gul, GA Esen, A Solinger, et al. Safe, Rapid-Onset, and Sustained Biological Activity of IL-1β Regulating Antibody XOMA 052 in Resistant Uveitis of Behcet's Preliminary Results of a Pilot Trial.2011; Behcet disease International Confferense.London.
 
8) Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet disease:Therapeutics. Ann Rheum Dis 2008; 67:1656-1662.
PubMed
9) Yasuoka H, Okazaki Y, Kawakami, et al. Autoreactive CD8+cytotoxic T lymphocytes to major histocompatiblity comples class I chain-related gene A in patients with Behcet disease. Arhtritis Rheum 2004; 50:3658-3662.
 
10) Kirino Y, Takeno M, Watanabe R, et al. Association of reduced heme oxygenase-1 with excessive Toll-like receptor 4 expression in peripheral blood mononuclear cells in Behcet disease. Arthritis Res Ther 2008:10:R16 Epub.
 
11) Kastner DL, Aksentijevich I, Goldbach-Mansky R, et al. Autoinflammatory disease reloaded:a clinical perspective. Cell 2010:140:784-790.
PubMed
12) Gul A. Behcet disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005:4:81-83.
PubMed
13) Masters SL, Simon A, Aksentijevich I, et al.Horror autoinflammaticus:the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009:27:621-668.
PubMed
14) Remmers EF, Cosan F, Kirino Y, et al. Common Variants of the Class I Major Histocompatibility Complex, IL 10, and IL23R/IL 12RB2 Genes Predispose to Behcet's Disease.Nat Genet 2010; 42:698-702.
 
15) Ideguchi H, Suda A, Takeno M, et al.Neurological manifestations of Behcet's disease in Japan:a study of 54 patients. J Neurol 2010; 257:1012-1020.
PubMed
P.60 掲載の参考文献
1) Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 1990; 57:85-89.
PubMed
2) Dougados M, Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum.1991; 34:1218-1227.
 
3) 井上康二. Spondyloarthropathy の早期診断. リウマチ病セミナーXVIII (七川歡次監修).2007; p40-49, 大阪, 永井書店.
 
4) Hukuda S, Minami M, Saito T, et al. Spondyloarthropathies in Japan:nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001; 28:554-559.
PubMed
5) 福田眞輔, 三浪三千男, 斉藤輝信ら.血清反応陰性関節炎患者の日本AS研究会第2回アンケート調査報告 日関外誌1999; 18:167-176.
 
6) 福田眞輔.わが国の脊椎関節炎の頻度.日本脊椎関節炎学会誌2009; 2:1-5.
 
7) 武仲善孝, 七川歓次, 廣田茂永.脊椎炎の有病率について. AS研究会抄録集1991:17.
 
8) 藤田豊久, 井上康二, 小宮靖弘, 川崎 拓ら.わが国における脊椎関節炎の有病率. 日本脊椎関節炎学会誌2010; 2:47-52.
 
9) 川崎 拓, 七川歓次.住民検診による痛風の疫学調査.痛風と核酸代謝2006; 30:66.
 
10) Rudwaleit M, Landewe R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I):classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68:770-776.
PubMed
11) Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II):validation and final selection. Ann Rheum Dis 2009:68:777-783.
PubMed
12) Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70:25-31.
PubMed
P.67 掲載の参考文献
1) Linn-Raskier SP, van der Helm-van Mil AHM, van Gaalen FA, et al. Smoking is a risk factor for ant-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006; 65:366-371.
 
2) Pedersen M, Jacobsen S, Klarlund M, et al. Environmental risk factors differ between rheumatoid arthritis with and wuthout auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006; 8:R133.
PubMed
3) Pedersen M, Jacobsen S, Garred P, et al. Strong combined gene-environment effect in anti-cyclic citrullinated peptide-positive rheumatoid arthritis. Arthritis Rheum 2007; 56:1445-1453.
 
4) Klareskog L, Stolt P, Lundberg H, et al. A new model for an etiology of rheumatoid arthritis:Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by cit rullination. Arthritis Rheum 2006; 54:38-46.
 
5) Klareskog L, Padyukov L, Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 2007; 19:49-54.
 
6) van der Helm-van Mil AHM, Verport KN, le Cessie S, et al. The HLA-DR shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007; 56:425-432.
 
7) van der Helm-van Mil AHM, Toes RE, Huizinga TWJ.Generic variants in the prediction of rheumatoid arthritis Ann Rheum Dis 2010; 969:1694-1696.
 
8) Michou L, Teixeira VH,Pierlot C, et al. Associations between genetic factors, tobacco smoking and auto-antibodies in familial and sporadic rheumatoid arthritis. Ann Rheum Dis 2008:57:465-470.
 
9) Lee HS, Irigoyen P, Kern M, et al. Interaction between smoking, the shared epitope, and ati-cyclic citrullinated peptide:A mixed picture in three large North American Rheumatoid Arthritis Cohorts. Arthritis Rheum 2007; 56:1745-1753.
 
10) Mikuls TR, Hughes L, Westfall AO, et al. Cigarette smoking, disease severity and autoantibody expression in african american with recent onset rheumatoid arthritis. Ann Rheum Dis:2008; 67:1529-1534.
PubMed
11) Kallberg H, Padyukov L, Plenge RM, et al.Gene-Gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arhtritis. Amer J Human Gnetics 2007; 80:867-875.
 
12) Morgan AW, Thomson W, Martin SG, et al. Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining suspectibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK caucasian population Arthritis Rheum 2009; 60:2565-2576.
 
13) Bang SY, Lee KH, Cho SK, et al. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated antibody status. Arthritis Rheum 2010:62:369-377.
PubMed
14) Mikulus TR, Sayles H, Yu H et al. Associations of cigarette smoking with rheumatoid arthritis in african americans. Arthritis Rheum 2010; 60:1-26.
 
15) Costenbader KH, Feskanich D, Mandl LA, et al. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Amer J Med 2006:119:650-658.
 
16) Costenbader KH, Chang S, De Vivo I, et al.Genetic polymorphisms in PTPN22, PADI 4, and CTLA-4 and risk evidence in two longitudinal cohort studies::evidence of gene-environment interactions with heavy cigarette smoking. Arthr Res Ther 2008; 10:R52:1-12.
 
17) Costenbader KH, Chang SH, Laden F.Geographic variation in rheumatoid arthritis among women in United States. Arch Inter Med 2008:168:1664-1670.
 
18) Karison EW, Chang S-C, Cui J, et al.Gene-environmental interaction between HLA-B1 shared epitope and heavy cigarette smoking predicting incident rheumatoid arthritis. Ann Rheum Dis 2010; 69:54-60.
 
19) Karison EW, Costenbader KH. Interpreting studies of interactions between RA risk factors. Rheumatology 2010; 6:72-73.
 
20) Lundstrom E, Kallberg H, Alfredsson L, et al Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis. Artritis Rheum 2009; 60:1597-1603.
 
21) Tobon GJ, Youinnou P, Saraux A. The environment, gen-epidemiology, and autoimmune disease:Rheumatoid arthritis. J Autoimmune Dis 2010; 35:10-14.
 
22) Del Puente A, Knowler WC, Pettitt DJ, et al.High incidence and prevalence of rheumatoid arthritis in Pima indians. Am J Epidemiol 1989; 129:1170-1178.
PubMed
23) Silman AJ, Ollier W, Holligan S, et al. Absence of rheumatoid arthrits in a rural Nigrian population. J Rheumatol 1993; 20:618-622.
 
24) Chou CT, Pei I, Chang DM, et al. Prevalence iof rheumatic diseases in Taiwan:a population study of urban, suburban, rural differences. J Rheumatol 1994; 21:302-306.
 
25) Carlens C, Hergens MP, Gruewald J, et al. Smoking, use of moist snuff, and risk of chronic inflammatory diseases. Am J Respir Crit Care Med 2010; 181:1217-1222.
 

骨関節, 脊椎, 神経

P.75 掲載の参考文献
1) 中田 研, 室井悠里, 大坪英則ら.半月板の再生医療:臨床応用への関門 日本整形外科学会誌2008; 82:647-653.
 
2) Nakata K, Shino K, Horibe S, et al. Arthroscopic anterior cruciate ligament reconstruction using fresh-frozen bone plug-free allogeneic tendons:10-year follow-up. Arthroscopy 2008:24:285-291.
PubMed
3) Louboutin H, Debarge R, Richou J, et al. Osteoarthritis in patients with anterior cruciate ligament rupture:a review of risk factors. Knee 2009; 16:239-244.
PubMed
4) Nakata K, Shino K, Hamada M, et al.Human meniscus cell:characterization of the primary culture and use for tissue engineering. ClinOrthop 2001; 391Suppl:S208-S218.
 
5) Muroi Y, Kakudo K, Nakata K. Effects of compressive load on human TMJ synovium-derived cells. J Dental Res 2007; 86:786-791.
 
6) Akamine Y, Muroi Y, Nakata K, et al. Cyclic mechanical loading to human synovial cells in three-dimensional cultured tissue up-regulates inflammatory cytokines and matrixmetalloproteinases Int J of Oral and Maxillofacial Surg (in press)
 
7) 中田 研, 天野 大, 岩橋 ら. Kinematics MRI新しい画像診断法.中村耕三, 吉川秀樹編集.整形外科 臨床パサージュ.3運動器画像診断マスターガイド.東京:中山書店; 2010:364-369.
 
P.82 掲載の参考文献
1) Myers SR, Eijer H, Ganz R. Anterior femoroacetabular impingement after periacetabular osteotomy. Clin Orthop Relat Res 1999; 363:93-99.
PubMed
2) Ganz R, Parvizi J, Beck M, et al. Femoroacetabular impingement:acause for osteoarthritis of the hip. Clin Orthop Relat Res 2003; 417:112-120.
 
3) Smith-Petersen MN. Treatment of malum coxae senilis, old slipped upper femoral epiphysis, intrapelvic protrusion of the acetabulum, and coxa plana by means of acetabuloplasty. J Bone Joint Surg Am 1936; 18:869-880.
 
4) Wenger DE, Kendell KR, Miner MR, et al. Acetabular labral tears rarely occur in the absence of bony abnormalities. Clin Orthop 2004; 426:145-150.
PubMed
5) Lavigne M, Parvizi J, Beck M, et al. Anterior femoroacetabular impingement, part I:techniques of joint preserving surgery. Clin Orthop Relat Res 2004; 418:61-66.
PubMed
6) Jamali AA, Mladenov K, Meyer DC, et al. Anteroposterior pelvic radiographs to assess acetabular retroversion:high validity of the "cross-over-sign". J Orthop Res 2007:25:758-765.
PubMed
7) Leunig M, Werlen S, Ungersbock A, et al. Evaluation of the acetabular labrum by MR arthrography. J Bone Joint Surg Br 1997:79:230-234.
PubMed
8) Gosvig KK, et al. Prevalence of Malformations of the Hip Joint and Their Relationship to Sex, Groin Pain, and Risk of Osteoarthritis:A Population-Based Survey J. Bone Joint Surg Am 2010; 92:1162-1169.
PubMed
9) Takeyama A, Naito M, Shiramizu K, et al. Prevalence of femoroacetabular impingement in Asian patents with osteoarthritis of the hip. Int Orthop (SICOT) 2009; 33:1229-1232.
 
10) Ganz R, Gill TJ, Gautier E, et al. Surgical dislocation of the adult hip. A technique with full access to the femoral head and acetabulum without the risk of avascular necrosis. J Bone Joint Surg Br 2001; 83:1119-1124.
 
11) Espinosa N, Rothenfluh D, Beck M, et al. Treatment of femoroacetabular impingement:preliminary results of labral refixation. J Bone Joint Surg Am 2006; 88A:925-935.
 
12) Philippon, MJ, Stubbs, AJ, Schenker ML, et al. Arthroscopic management of femoroacetabular impingement:Osteoplasty technique and literature review. Am J Sports Med 2007:35:1571-1580.
PubMed
13) Philippon, MJ, Briggs KK, Yen YM, et al. Outcomes following hip arthroscopy for femoroacetabular impingement with associated chondrolabral dysfunction. J Bone Joint Surg Br 2009; 91:16-23.
PubMed
P.88 掲載の参考文献
1) 七川歡次:強直性脊椎炎と付着部炎再訪.七川歡次監修. リウマチ病セミナーXIII.大阪:永井書店; 2002:48-54.
 
2) 川崎 拓:Enthesitis (付着部炎) の画像診断.七川歡次監修.リウマチ病セミナーXVII.大阪:永井書店; 2006:145-153.
 
3) Niepel GA, Sitaj S. Enthesopathy. Clin Rheum Dis 1979; 5:857-872.
 
4) Dolgo-Saburoff B:Uber Ursprung und Insertion der Skeletmuskeln Anatomischer Anzeiger 1929; 68:80-87.
 
5) Schnider H.Zur Struktur der Sehnenansatzzonen.Zeitchrift for Anatomie und Entwicklungs-geschichte 1956; 119:431-456.
 
6) Cooper RR, Misol S. Tendon and ligament insertion. A light and electron microscopic study. J. Bone Joint Surg 1970; 52A:1-20.
 
7) Benjamin M, Ralphs JR. Fibrocartilage in tendons and ligaments-an adaptation to compressive load. J Anat 1998; 193:48 1-494.
 
8) Benjamin M, Kumai T, Milz S, et al. The skeletal attachment of tendons? tendon'entheses'. Comp Biochem Physiol 2002:133A:931-945.
 
9) Knese K-H, Stutzgewebe und Skelettsystem. In:Mollendorff, W. Von, Bargmann, W.(Eds.), Handbuch der mikroskopischen Anatomie des Menschen II/5. Berlin:Springer-Verlag; 1979:1-938.
 
10) Woo SL-Y, Maynard J, Butler D, et al.Ligament, tendon, and joint capsule insertions to bone. In:Woo SL-Y, Buckwalter JA (Eds.), Injury and Repair of the Musculoskeletal Soft Tissues. Illinois. IL:American Acadeny of Orthopaedis Suugeons:1988; 133-166.
 
11) Benjamin M, Ralphs JR. Functional and developmental anatomy of tendons and ligaments. In:Gordon SL, Blair SJ, Fine LJ.(Eds.), Rosemont, IL:Repetitive Motion Disorders of the Upper Extremity. American Academy of Orthopaedic Surgeons:1995:185-203.
 
12) Milz S, Rufai A, Buettner A, et al. Three dimensional reconstructions of the Achilles tendon insertion in Man J Anat 2002; 200:145-152.
 
13) Moriggl B, Kumai T, Milz S, et al. The structure and histopathology of the `enthesis organ:at the navicular insertion of the tendon of tibialis posterior in man. J Rheumatol 2003; 30:508-517.
 
14) Gao J, Messner K, Ralphs JR, et al. An immunohistochemical study of enthesis development in the medial collateral ligament of the rat knee joint. Anat. Embryol 1996; 194:399-406.
PubMed
15) Rufai A, Ralphs JR, Benjamin M, et al. Structure and histopathology of the insertional region of the human Achilles tendon. J Orthop Res 1995:13:585-593,
PubMed
P.96 掲載の参考文献
1) Goldthwait JE, Osgood RB. A consideration of the pelvic articulations from an anatomical, pathological and clonical standpoint. Boston Med Surg J 1905; 152:593-601.
 
2) Mixter WJ, Barr JS. Rupture of the intervertebral disc with involvement of the spinal canal.N Engl J Med 1934; 211:210-215.
 
3) 博田節夫. AKA関節運動学的アプローチ第2版.東京:医歯薬出版; 2010:p56.
 
4) 中川富雄.日本人仙腸関節および近接域の神経細末の分布に関する研究.日本整形外科会誌1966; 40:419-430.
 
5) Hodgson BF, et al. Pyrogeric sacroiliac joint infection. Clin Orthop 1989; 246:146-149.
PubMed
6) Doita M, Yoshiya S, Nabeshima Y, et al. Acute Pyogenic Sacroiliitis Predisposing Conditions. Spine 2003:28:F384-389.
 
7) 村上栄一.仙腸関節由来の腰痛.日本腰痛会誌2007; 13:40-47.
 
8) 村上栄一, 菅野晴夫, 奥野洋史ら.仙腸関節性腰殿部痛の診断と治療.MB Orthop 2005; 18:77-83.
 
9) Fortin JD, Falco FJE. The Fortin finger test:an indicator of sacroiliac pain. The Am J Orthop 1997; 26:477-480.
 
10) Berthelot JM, Laslett M. Par quells signes cliniques s' assurer au mieux qu'une douleur est bien d' origine sacro-iliaque (sensu lato)? Rev Rhum 2009; 76:741-749.
 
11) 村田 亮, 廣瀬 彰, 坂本雅昭.骨シンチグラムで取り込みを示さなかった化膿性仙腸関節炎の1例.整形外科2000; 51:1535-1538.
 
12) 吉岡浩之, 織田弘美, 二ノ宮節夫ら.小児化膿性仙腸関節炎の診断と治療.リウマチ科2005; 33:217-222.
 
13) 桂木 誠, 西原春實, 荒木昭輝ら.化膿性仙腸関節炎の画像診断.画像診断2004; 24:82-88.
 
P.112 掲載の参考文献
1) 財団法人厚生統計協会編集 発行.第4章 健康状況と受療状況.国民衛生の動向・厚生の指針2009;増刊 56 (9):74-80, 440-441.
 
2) 西林保朗.高齢者後弯の病態-新しい概念でとらえるべき前屈症-.七川歡次監修.リウマチ病セミナー V.大阪:永井書店; 1994:121-132.
 
3) 西林保朗.若年者の椎間板.七川歓次監修.リウマチ病セミナー VI.大阪:永井書店; 1995:102-118.
 
4) 西林保朗.腰背痛の慢性化とその予防-線維化と線溶系異常を中心に-.七川歡次監修.リウマチ病セミナーVIII.大阪:永井書店; 1997:120-133.
 
5) 西林保朗. Camptocormia-前屈症:高齢社会で問題となる脊柱変形 高齢者後弯-.七川歡次監修.リウマチ病セミナーXV.大阪:永井書店; 2004:69-86.
 
6) 西林保朗, 吉本沙織筋筋膜痛症候群.七川歡次監修.リウマチ病セミナーXVII.大阪:永井書店:2006:101-113.
 
7) 西林保朗.線維筋痛症のレゾンデートル-運動器疾患患者の全人的ケアへのいざない-.七川歡次監修.リウマチ病セミナーXIX大阪:永井書店; 2008:58-67.
 
8) 西林保朗.星状神経節の臨床-温故知新:"健康とは"からアプローチする全人的ケア-七川歡次監修.リウマチ病セミナーXXI.大阪:永井書店; 2010:108-119.
 
9) 星野雄-, 篠原光正, 星地亜都司ら.特発性頸椎後轡症-いわゆる首下がり-J Spinal Research 2010; 2:147-153.
 
10) 平岩利仁, 堀岳 史, 安田剛敏ら.頸椎症に合併した首下がり症の2例.整・災外2011; 54:415-418.
 
11) 大田 亮, 田中信弘, 中西-義ら.首下がり症例に対し, ナビゲーションシステムを用いて頸椎後方固定術を施行した2例.中部整災誌2010:53:951-952.
 
12) 岡本義之, 河原範夫, 村上英樹ら. Cervical flexion myelopathyの2例.中部整災誌2010:53:205-206.
 
13) 田中誠人, 上田百合人, 小泉宗久ら.当科で経験した首下がり.中部整災誌2010:53:221-222.
 
14) 古川哲雄.2.正常人にみられるneglect syndrome.続ヤヌスの顔-背面思考の神経内科学-.東京:科学評論社:1992:4-11.
 
15) 西林保朗.靭帯のhyperlaxityと過度運動性症候群.七川歡次監修.リウマチ病セミナーX.大阪:永井書店:1999:114-132.
 
16) Kirkaldy-Willis WH. Section 1. Chaper 5. Pathology and pathogenesis of low back pain. Kirkaldy-Wil-lis WH, Bernard Jr TN, Ed In Managing low back pain.4th ed New York:Churchill Livingstone; 1999:65-96.
 
17) Koehler A, Zimmer EA.5. Vertebral Column, Lumbar Spine. In Borderlands of the normal and early pathologic in skeletal roentgenology.4th ed.New York:Georg ThiemeVerlag; 1993:530-566.
 
18) 西林保朗監修.ポジティブ・エクササイズ (パンフレット, ポスター, DVD).日経メディカル開発 (提供:参天製薬株式会社), 2007.
 
19) Kita K, Hujino K, Nasu T, et al. A simple protocol for preventing falls and fractures in elderly individuals with musculoskeletal disease. Osteoporosis Int 2007; 18:611-619.
 
20) 西林保朗.変形膝関節症の痛みはどこのもの?講演集.七川歡次監修-近畿リウマチ病研究会-.近畿リウマチ病研究会; 2002:39-45.
 
P.120 掲載の参考文献
1) Zataruk MN, Violan MA, ZurakowskiD, et al. Karate injuries in children and adolescents. Accid Anal Prev 2000; 32:421-425.
 
2) Destombe C, Lejeune L, Guillodo Y, et al. Incidense and nature of Karate injuries. Joint Bone Spine 2006; 73:182-188.
 
3) 高橋晃弘, 樋口謙次, 大澤智恵子ら.高等学校空手道選手におけるスポーツ障害について.骨・関節系理学療法2003; 5:40.
 
4) Arriaza R, Leyes M. Injury profile in competitive karate:prospective analysis of three consecutive Word Karate Championships. Knee Surg Sports Traumatol Arthrosc 2005; 13:6003-6007.
 
5) Macan J, Bundalo VD, RomicG. Effect of the new karate rules on the incidence and distribution of injuries. Br Sports Med 2006:40:326-330.
 
6) AndoK, MoriyamaK, HosokawwaY, et al. Excessive schivering after remifetanil infusion in a muscular karate player for tracheal resection and construction surgery. Masui 2010; 59:504-506.
 
7) NappoA, VaresiC, RossiL, et al. Sudden cardiac death in non-professional athletes. Pathologica 1997:89; 517-522.
 

燐・カルシウム代謝

P.126 掲載の参考文献
1) Tolar J, teitelbaum SL, Orcahrd PJ. Osteoporosis.N Engl J med 2004:351:2839-2849.
 
2) Whyte MP, Wenkert D, Clemens KL, et al. Bisphosphonate-induced osteopetrosis.N Engl J Med 2003:349:457-463.
 
3) Odvina CV, Zerwekh J, Rao S, et al. Severely suppressed bone turnover:a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294-1301.
 
4) Borah B, Dufresne TE, Ritman EL, et al.Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture:sequential triple biopsy studies with micro-com-puted tomography. Bone 2006; 39:345-352.
 
5) Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zoledronic acid once yearly on bone re-modeling and bone structure. J Bone Min Res 2008; 23:6-16.
 
6) Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw:report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479-1491.
 
7) Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy. J Bone Joint Surg Br 2007; 89:349-353.
PubMed
8) Stephan JJ, Burr DB, Pavo I, et al.Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007:41:378-385.
 
9) Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment:the Fracture Intervention Trial longterm extension (FLEX):a randomized trial. JAMA 2006; 296:2927-2938.
 
10) Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000; 85:720-726.
PubMed
11) Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65:369-376.
 
12) Somford MP, Geurts GF, den Teuling JW, et al.Long-Term Alendronate Use Not without Consequences? Int J Rheumatol 2009:253432-37.
PubMed
13) Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15:613-620.
PubMed
14) Boivin T, Chadoeuf J, Bouvier JC, et al. Modelling the interactions between phenology and insecticide resistance genes in the codling moth Cydia pomonella Bone 2000; 27:687-694.
 
15) Saito M, Marumo K. Collagen cross-links as a determinant of bone quality:a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010; 21:195-214.
PubMed

検査, 評価

P.131 掲載の参考文献
1) Bae CJ, Foldvary-Schaefer N.Normal Human Sleep in Clinical Sleep Disorders. Carney PR, Berry RB, Geyer JD, eds.Lippincott Williams&Wilkins; 2005:29-37.
 
2) 大野良之.難病対策概要と生活習慣要因との関連.大野良之, 柳川洋編.生活習慣病予防マニュアル改定4版.東京:南山堂; 2006:91-96.
 
3) 志水正敏.関節リウマチと閉塞性睡眠障害.七川歓次監修.リウマチ病セミナーXIV.大阪:永井書店; 2003:194-202.
 
4) 立花直子.睡眠の質の評価と改善法.七川歓次監修.リウマチ病セミナーXVII.大阪:永井書店; 2004:142-149.
 
5) 志水正敏.上気道抵抗症候群.七川歓次監修.リウマチ病セミナー XVII.大阪:永井書店:2006:76-82.
 
6) 志水正敏.脳とリウマチ病.七川歓次監修.リウマチ病セミナーXXI.大阪:永井書店; 2007:164-169.
 
7) Moldofsky H. Rheumatic manifestation of sleep disorders. Curr Opin Rheumatol 2010; 22:59-63.
PubMed
8) Bangash MF, Xie A, Skatrud JB, et al. Cerebrovascular response to arousal from NREM and REM sleep. Sleep 2008; 31:321-327.
PubMed
9) 麻野井英次.睡眠時無呼吸症候群.麻野井英次編, 循環器科医必須知識東京; メジカルビュー社:2008.
 
10) 志水正敏RAと心血管イベント.七川歓次監修.リウマチ病セミナーXVIII.大阪:永井書店; 2007:1-7.
 
11) Quan SF, Howard BV, Iber C, et al. The Sleep Heart Health Study:Design, Rationale, And Methods. Sleep 1997:20:1077-1085.
PubMed
12) Caffo B, Diener-West M, Punjabi NM, et al. A novel approach to prediction of mild obstructive sleep disordered breathing in a population-based sample:the Sleep Heart Health Study. Sleep 2010:33:1641-1648.
 
13) Parish JM. Sleep-Related Problems in Common Medical Conditions. CHEST 2009; 135:563-572.
PubMed
14) 綜合臨牀:2011年8月号特集「睡眠呼吸障害と全身性疾患」大阪:永井書店.
 
P.139 掲載の参考文献
1) Nienhuis RLF, Mandema EA. A new serum factor in patients with rheumatoid arthritis. The antiperi-nuclear factor. Ann Rheum Dis 1964; 23:302-305.
 
2) Young BJ, Mallya RK, Leslie RD, et al. Antikeratin antibodies in rheumatoid arthritis. Br Med J 1979; 2:97-99.
PubMed
3) Sebbag M, Simon M, Vincent C, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995:95:2672-2679.
PubMed
4) Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis?specific autoantibodies. J Clin Invest 1998; 101:273-281.
PubMed
5) Shellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155-163.
 
6) van Venrooij WJ, Hazes JM, Visser H, et al. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis.Neth J Med 2002; 60:383-388.
PubMed
7) Alessandori C, Bombardieri M, Papa N, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFαtherapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004:63:1218-1221.
 
8) Braun-Moscovici Y, Markovits D, Zinder O, et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 2006; 33 (3):497-500.
PubMed
9) van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 2008; 1143:268-285.
PubMed
10) Bas S, Genevay S, Meyer O, et al. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003:42:677-680.
PubMed
11) Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003:62:120-126.
PubMed
12) Forslind K, Ahlmen M, Eberhardt K, et al. Prediction of radiological outcome in early RA in clinical practice:role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004:63:1090-1095.
 
13) van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005; 7:R949-R958.
PubMed
14) Rantap??-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheurn 2003; 48:2741-2749.
 
15) Nielen MMJ, van Schaardenburg D, Reesink HWR, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis:a study of serial measurements in blood donors. Arthritis Rheum 2004; 50:380-386.
 
16) van Gaalen FA, Linn-Rasker SP, van Venrooiji WJ, et al. Autoantibodies to cyclic citrullinated peptides (CCP) predict progression to rheumatoid arthritis in patients with undifferentiated arthritis:a prospective cohort study. Arthritis Rheum 2004; 50:709-715.
 
17) Vittecoq O, Incaurgarat B, Jouen-Beades F, et al. Autoantibodies recognozing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 2003; 135:173-180.
 
18) Eriko Kudo-Tanaka, Shiro Ohshima, Yukihiko Saeki, et al. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis (RA) in early undifferentiated arthritis. Clinical Rheumatol 2007; 26:1627-1633.
PubMed
19) Tamai M, Kawakami A, Uetani M, et al. Early prediction of rheumatoid arthritis by serological variables and magnetic resonance imaging of the wrists and finger joints:results from prospective clinical examination. Ann Rheum Dis 2006; 65:134-135.
PubMed
20) Silman AJ, Hawker GA, Aletaha D. The 2009 ACR/ARHP Annual Scientific Meeting Arthritis& Rheumatism, Volume60, 0ctober 16-21, 2009, Philadelphia. Abstract Supplement.
 
21) Aletaha D, Neogi T, Silman AJ, et al.2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569-2581.
PubMed
22) van Dongen H, van Aken J, Lard LR, et al. Efficacy of Methotrexate treatment in patients with probable rheumatoid arthritis. Arthritis Rheum 2007; 56:1424-1432.
PubMed
23) Ohmura K, Terao C, Maruya E, et al. Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset:a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. Rheumatology (Oxford) 2010; 49:2298-2304.
PubMed
24) van der Helm-van Mil AH, Verpoort KN, le Cessie S, et al. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007; 56:425-432.
PubMed
P.145 掲載の参考文献
1) Hukuda S, Minami M, Saito T, et al. Spondyloarthropathies in Japan:nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001; 28:554-559.
PubMed
2) 武仲善孝, 七川歡次, 廣田茂永.脊椎炎の有病率について.-三重県阿山町のリウマチ病検診から.第1回AS研究会抄録集.大阪:1991:17.
 
3) 藤田豊久, 井上康二, 小宮靖弘ら.わが国における脊椎関節炎の有病率.日本脊椎関節炎学会誌2010; 1:47-52.
 
4) Amor B, Dougados M, Mijiyama M. Critere de classification des spondyloarthropathies. Rev Rheum 1989; 57:85-89.
 
5) Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34:1218-1227.
 
6) Aletaha D, Neogi T, Silman AJ, et al.2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580-1588.
PubMed
7) Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants.Nat Genet 2007; 39:1329-1337.
 
8) Wendling D. Interleukin 23:a key cytokine in chronic inflammatory disease. Joint Bone Spine 2008; 75:517-519.
PubMed
9) Oppmann B, Lesley R, Blom B, et al.Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13:715-725.
 
10) Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199:125-130.
PubMed
11) Wang X, Lin Z, Wei Q, et al. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int 2009; 29:1343-1347.
 
12) Cua DJ. Sherlock J. Chen Y. Et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.Nature 2003; 421:744-748.
PubMed
13) Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116:1310-1316.
 
14) Paradowska-Gorycka A, Grzybowska-Kowalczyk A, Wojtecka-Lukasik E, et al. IL-23 in the pathogenesis of rheumatoid arthritis. Scand J Immunol 2010; 71:134145.
 
15) Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116:1218-1222.
PubMed
16) Chen L, Wei XQ, Evans B, et al. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol 2008; 38:2845-2854.
 
17) Kotake S, Udagawa N, Takahashi N, et al. IL-17in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999:103:1345-1352.
 
18) Rueda B, Orozco G, Raya E, et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis 2008:67:1451-1454.
PubMed
19) Rahman P, Inman RD, Gladman DD, et al. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008; 58:1020-1025.
PubMed
20) Karaderi T, Harvey D, Farrar C, et al. Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series. Rheumatology (Oxford) 2009; 48:386-389.
PubMed
21) Pimentel-Santos FM, Ligeiro D, Matos M, et al. Association of IL23R and ERAP1 genes with ankylosing spondylitis in a Portuguese population. Clin Exp Rheumatol 2009; 27:800-806.
 
22) Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461-1463.
PubMed
23) Dubinsky MC, Wang D, Picornell Y, et al. IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm Bowel Dis 2007; 13:511-515.
PubMed
24) Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hurn Genet 2007; 80:273-290.
 
25) Lew W, Chang JY, Jung JY, et al. Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behcet's disease. Br J Dermatol 2008; 158:505-511.
PubMed
26) Chabaud M, Durand JM, Buchs N, et al.Human interleukin-17:A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42:963-970.
 
27) Wong CK, Ho CY, Li EK, et al. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus.Lupus 2000:9:589-593.
PubMed
28) Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43:2455-2463.
PubMed
29) Teunissen MB, Koomen CW, de Waal Malefyt R, et al. Interleukin-17and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111:645-649.
 
30) Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128:1207-1211.
PubMed
31) Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease.Gut 2003:52:65-70.
PubMed
32) Wendling D, Cedoz JP, Racadot E, et al, Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007:74:304-305.
PubMed
33) Wendling D, Cedoz JP, Racadot E. Serum and synovial fluid levels of p40 1L12/23 in spondyloarthropathy patients. Clin Rheumatol 2009; 28:187-190.
 
34) Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol 2007; 34:2285-2290.
PubMed
35) Kim HR, Cho ML, Kim KW, et al.Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB-and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford) 2007; 46:57-64.
PubMed
36) Kim HR, Kim HS, Park MK, et al. The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol 2007; 36:259-264.
PubMed
37) Kageyama Y, Kobayashi H, Kato N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod Rheumatol 2009; 19:657-662.
 

生物化学反応

P.154 掲載の参考文献
1) Oh SB, Tran PB, Samantha E, et al. Chemokines and Glycoprotein120 Produce Pain Hypersensitivity by Directly Exciting Primary Nociceptive Neurons The Journal of Neuroscience 2001; 21:5027-5035.
 
2) White FA, Jung H, Miller RJ:Chemokines and the pathophysiology of neuropathic pain. PNAS 2007; 104, 51:20155.
 
3) Charo IF, Ransohoff RM:The many roles of chemokines and chemokine receptors in inflammation.N Engl J Med 2006; 354:610-621,
PubMed
4) Jung H, Toth PT, Fletcher A:White Monocyte chemoattractant protein-1 functions as a neuromodulator in the dorsal root ganglia neurons. J Neurochem 2008; 104:254-263.
PubMed
5) Rittner HL, Machelska H, Stein CJ:Leukocytes in the regulation of pain and analgesia.Leukoc Biol 2005; 78:1215-1222.
 
6) Zubieta JK, Smith YR, Bueller JA, et al:mu-opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci 2002; 22:5100-5107.
PubMed
7) Trecki J, Brailoiu GC, Ellen M, et al:Localization of CXCR4 in the forebrain of the adult rat. Brain Res 2010; 1315C:53-62.
 
P.161 掲載の参考文献
1) Stoll S, Delon J, Brotz TM, et al. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 2002; 296:1873-1876.
PubMed
2) Miller MJ, Wei SH, Parker I, et al. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 2002; 296:1869-1873.
PubMed
3) Germain RN, Baj?noff M, Castellino F, et al. Making friends in out-of-the-way places:how cells of the immune system get together and how they conduct their business as revealed by intravital imaging. Immunol Rev 2008; 221:163-181.
 
4) Ishii M, Egen JG, Klauschen F, et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis.Nature 2009; 458:524-528.
PubMed
5) Klauschen F, Ishii M, Qi H, et al.Quantifying cellular interaction dynamics in 3-D fluorescence microscopy data.Nature Protoc 2009:4:1305-1311.
 
6) Ishii M, Kikuta J, Shimazu Y, et al. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med 2010:207:2793-2798.
PubMed
7) Kikuta J, Iwai K, Saeki Y, Ishii M. S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis. Rheumatol. Int.2011 (in press).
 
8) Ishii T, Ishii M. Intravital two-photon imaging:aversatile tool for dissecting the immune system. Ann Rheum Dis 2011:70 Suppl 1:i113-i115.
 
9) Ishii T, Shimazu Y, Nishiyama I, et al. The role of sphingosine 1-phosphate in migration of osteoclast precursors ; an application of intravital two-photon microscopy. Mol Cells 2011:31:399-403.
PubMed
10) Ishii T, Kawamura S, Nishiyama I, et al.Use of intravital microscopy and in vitro chemotaxis assays to study the roles of sphingosine-1-phosphate in bone homeostasis. Methods Mol Biol.2011, in press.
 

治療と副作用

P.166 掲載の参考文献
1) Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis.Lancet 2010; 376:1094-108.
PubMed
2) Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis.Lancet 2009; 373:659-672.
PubMed
3) Smolen JS, Landewer, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964-975.
PubMed
4) Aletaha D, Neogi T, Silman A, et al.2010 Rheumatoid arthritis classification criteria. Arthritis Rheum 2010; 62:2569-2581.
PubMed
5) Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis 2010; 69:631-637.
PubMed
6) Felson DT, Smolen JS, Wells G, et al. American college of rheumatology/european league againstrheumatism provisional definition of remission in rheumatoid arthritis forclinical trials. Ann Rheum Dis 2011; 70:404-413.
 
7) Tanaka Y, Takeuchi T, Mimori T, et al. For the RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis:RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010:69:1286-1291.
 
8) Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis:a randomized trial. Ann Intern Med 2007; 146:406-415.
PubMed
9) Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, et al. The impact of four dynamic,goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritispatients in the Best study. Ann Rheum Dis (in press)
 
10) Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008; 18:460-464.
PubMed
P.172 掲載の参考文献
1) Kim Seo Young, Solomon Daniel H. Tumor necrosis factor blockade and the risk of viral infection.Nat Rev/Rheumatol 2010; 6:165-174.
PubMed
2) McDonaid Jay R, Zeringue Angelique L, Caplan Liron, et al.Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48:1364-1371.
 
3) Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67:189-194.
PubMed
4) レミケード(R), 点滴静注用100 関節リウマチ 適正使用情報 使用成績調査 (全例調査) における5,000例の安全性プロファイル (田辺三菱製薬) 2007年10月作成.
 
5) 針谷正祥.特集リウマチ性疾患診療における日本のエビデンスわが国におけるエタネルセプトの安全性と有効性.リウマチ科2009; 41:8-19.
 
6) エンブレル(R)皮下注用25mg適正使用情報Vol. 9, 全例調査結果について (ワイス株式会社, 武田薬品工業株式会社) 2008年12月作成.
 
7) ヒュミラ(R)皮下注40mgシリンジ0.8mL適正使用情報Vol.4 (3.084例中間報告概要) (Eisai, Abbott) 2009年10月作成.
 
8) アクテムラ(R)点滴静注用80mg, 200mg, 400mg安全性情報Vol.3.全例調査の中間報告「関節リウマチ」「多関節に活動性を有する若年性特発性関節炎」 (中外製薬株式会社) 2010年12月改訂.
 
9) オレンシア(R)点滴静注用250mg適正使用情報Vol.2.(ブリストル・マイヤーズ株式会社) 2011年7月作成
 
10) Torre-Cisneros J, del Castillo M, Caston J J, et al. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology 2005; 44:1132-1135.
 
11) Alspaugh M, Henle G, Lennette E, et al. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. J Clin Invest 1981; 67:1134-1140.
PubMed
12) Balandraud N, Guis S, Meynard J B et al.Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase Epstein-Barr virus load in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57:762-767.
 
13) Haerter G, Manfras BJ, Jong-Hesse Y dJ, et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpfa antibody therapy for rheumatoid arthritis. Clin Infect is 2004; 39:88-94.
 
14) Umemura T, Tanaka E, Kiyosawa K, et al. Japan de novo Hepatitis B Research Group. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008; 47:52-56.
 
15) Galabrese LH, Zein NN, Vassilopoulos D. Review Hepatitis B virus (HBV) reactivation with immuno-suppressive therapy in rheumatic diseases:assessment and preventive strategies. Ann Rheum Dis 2006; 65:983-989.
 
16) Carroll MB, Bond MI.Use of tumor necrosis factor-α inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2007; 38:208-217.
 
17) Zingarelli S, Airo P, Frassi M, et al. Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo 2008; 60:22-27.
PubMed
18) Chung SJ, Kim JK, Park MC, et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-αtherapy. The Journal of Rheumatology 2009; 36:2416-2420.
 
19) Kenneth G Saag, Gim Gee Teng, Nivedita M Patkar, et al. American College of Rheumatology 2008:Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis & Rheumatism (Arthritis Care & Research) 2008; 59:762-784.
PubMed
20) 坪内博仁, 熊田博光, 清澤研道ら.免疫抑制・化学療法により発症するB型肝炎対策-厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告-.肝臓2009:50:38-42.
 
21) 竹内孝男. B型肝炎ウイルス陽性にもかかわらずMTX, エタネルセプトを投与し, 寛解状態が持続出来て いる関節リウマチの1症例.臨床リウマチ2009; 21:380-384.
 
22) Roux C H, Brocq O, Breuil V, et al. Safety of anti-TNF-αtherapy in rheumatoid and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006; 45:1294-1297.
 
23) Mahajan TD, Hooker R, Maher L et al. Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection. J Clin Rheumatol 2010; 7; 332-334.
PubMed
24) Galabrese LH, Zein N, Vassilopoulos D, et al, Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections:hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004:63:18-24.
 
25) Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatrnent-naive patients with chronic hepatitis C virus infection:a phase 2 randomized, double-blind, placebo-controlled atudy. J Hepatol 2005; 42:315-322.
 
26) Ferri G, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-α-therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. The Journal of Rheumatology 2008; 35:1944-1949.
 
27) Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Current Opinion in Rheumatology 2010; 22:443-450.
 
28) Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003:62:1078-1082.
 
P.181 掲載の参考文献
1) Jennette JC, Falk RJ, Andrassy K, et al.Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-192.
PubMed
2) 尾崎承一.血管炎症候群の病態と治療の新しい考え方.内科学会雑誌2010; 99:31.
 
3) Fauci AS, Haynes BF, Katz P , Wolff SM.Wegener's granulomatosisi:prospective clinical and therapeutic experience with 85 patinets for 21 years. Ann Inter Med 1983; 98:76-85.
 
4) Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310-317.
PubMed
5) Kinjoh K, Kyogoku M, Good RA.Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis. Proc Natl Acad Sci USA 1993; 90:3413-3417.
PubMed
6) Yumura W, Itabashi M, Ishida-Okawara A, et al. A novel mouse model for MPO-ANCA-associated glomerulonephritis. Microbiol Immunol 2006; 50:149-157.
PubMed
7) Edens WA, Sharling L, Cheng G, et al. Tyrosine cross-linking of extracellular matrix is catalyzed by Duox, a multidomain oxidase/peroxidase with homology to the phagocyte oxidase subunit gp91 phox. J Cell Biol 2001:154:879-891.
 
8) Chen M, Kallenberg CG, ANCA-associated vasculitis-advances in pathogenesis and treatment.Nat Rev Rheumatol 2010; 6:653-664.
PubMed
9) Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.N Engl J Med 2010:363:221-232.
PubMed
10) Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide for ANCA-associated renal vasculitis.N Engl J Med 2010; 363:211-220.
PubMed
11) Vincenti F, Cohen SD, Appel G.Novel B cell therapeutic target in transplantation and immune-mediated glomerular diseases. Clin J Am Soc Nephrol 2010; 5:142-151.
 
P.189 掲載の参考文献
1) Chan TM.Lupus nephritis:induction therapy.Lupus 2005; 14:s27-s32.
PubMed
2) Boumpas DT, Austin HA III, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.Lancet 1992; 340:741-745.
 
3) Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.N Engl J Med 1986:314:614-619.
 
4) Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67:95-205,
 
5) Boumpas DT, Bertsias GK, Balow JE. A decade of mycophenolate mofetil for lupus nephritis:is the glass half-empty or half-full? Ann Rheum Dis 2010; 69:2059-2061.
PubMed
6) Waldman M, Appel GB.Update on the treatment of lupus nephritis. Kidney Int 2006; 70:1403-1412.
PubMed
7) 片田圭宜.ミコフェノール酸モフェチル (MMF) によるループス腎炎の治療.七川歓次監修, リウマチ病 セミナーXVI.大阪:永井書店:2005:242-246.
 
8) Allison AC. Mechanisms of action of mycophenolate mofetil.Lupus 2005; 14:s2-s8.
PubMed
9) Chan TM, Li FK, Tang CS, Wong RW, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis.Hong Kong-Guangzhou Nephrology Study Group.N Engl J Med 2000; 343:1156-1162.
 
10) Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.N Engl J Med 2005; 353:2219-2228.
 
11) Chan TM, Tse KC, Tang CS, et al.Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16:1076-1084.
PubMed
12) Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis.N Engl J Med 2004; 350:971-980.
PubMed
13) Ginzler EM, Wofsy D, Isenberg D, et al.Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis:findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010; 62:211-221.
PubMed
14) Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis:a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2:968-975.
PubMed
15) Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006; 8:R182.
PubMed
16) Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis:a meta-analysis of randomized controlled trials.Nephrol Dial Transplant 2007; 22:1933-1942.
PubMed
17) Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103-1112.
PubMed
18) Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis:a systematic review and metaanalysis. J Rheumatol 2011; 38:69-78.
PubMed
19) 野島美久.自己免疫疾患治療におけるミコフェノール酸モフェチル(MMF)の位置づけ.炎症と免疫2007; 15:341-347.
 
20) Lertdumrongluk P, Somparn P, Kittanamongkolchai W, et al. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int 2010; 78:389-395.
PubMed
21) Zahr N, Arnaud L, Marquet P, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum 2010; 62:2047-2054.
PubMed
22) Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis:results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010:69:2083-2089.
PubMed
23) Rouster-Stevens KA, Morgan GA, Wang D, et al. Mycophenolate mofetil:a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62:1446-1451.
PubMed
24) Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant derrnatomyositis. Arch Dermatol 2006; 142:65-69.
PubMed
25) Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept):an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005; 44:386-389.
PubMed
26) Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940-944.
PubMed
27) Vanthuyne M, Blockmans D, Westhovens R, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007; 25:287-292.
PubMed
28) Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008:133:455-460.
PubMed
29) Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006; 45:1005-1008.
PubMed
30) Nihtyanova SI, Brough GM, Black CM, et al, Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) 2007; 46:442-445.
PubMed
31) Zamora AC, Wolters PJ, Collard HR, et al.Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008; 102:150-155.
PubMed
32) Koutroumpas A, Ziogas A, Alexiou I, et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010; 29:1167-1168.
PubMed
33) Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35:630-640.
 
34) 塩沢俊一.膠原病学2011; 丸善:第4版.
 
P.200 掲載の参考文献
1) Cosnes J, Cattan S, Blain A, et al.Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8:244-250.
PubMed
2) Hanauer SB, Feagan BG, Lichtenstein GR, et al, Maintenance infliximab for Crohn's disease:the ACCENT I randomised trial, Lancet 2002; 359:1541-1549.
PubMed
3) Sands BE, et al.Long-Term Treatment of Fistulizing Crohns Disease:Response to Infliximab in the ACCENT If Trial through54 Weeks.Gastroenterology 2002; 122 (Suppl.4):A136.
 
4) Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases.Gastroenterology 2009; 136:1182-1197.
PubMed
5) Waugh AW, Garg S, Matic K, et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab:long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010; 32:1129-1134.
PubMed
6) Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease.Gastroenterology 1990; 99:956-963.
PubMed
P.207 掲載の参考文献
1) Assoun J, Richardi G, Railhac JJ, et al. Osteoid osteoma:MR imaging versus CT. Radiology 1994; 191:217-223.
PubMed
2) Makley JT, Dunn MJ. Prostaglandin synthesis by osteoid osteoma.Lancet 1982; 2 (8288):42.
PubMed
3) Okuda S, Myoui A, Nakase T, et al. Ossification of the ligamentum flavum associated with osteoblastoma:a report of three cases. Skeletal Radiol.2001; 30 (7):402-6.
PubMed
4) De Boeck H, Casteleyn PP, Bossuyt A, et al. Intraoperative radioactive localization of small bone tumours. Int Orthop.1992; 16 (2):172-5.
PubMed
5) Kendoff D, Hufner T, Citak M, et al.Navigated Iso-C3D-based percutaneous osteoid osteoma resection:a preliminary clinical report. Comput Aided Surg 2005:10:157-163.
PubMed
6) 名井 陽, 菅野伸彦, 小山 毅, ら.骨盤類骨骨腫に対するナビゲーションを利用した小侵襲切除術.整形外科2004; 55 (11):1466-1467.
 
7) Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR 1996; 167:759-768.
PubMed
8) Rosenthal DI, Alexander A, Rosenberg AE, et al. Ablation of osteoid osteomas with a percutaneously placed electrode:a new procedure. Radiology 1992; 183:29-33.
PubMed
9) de Berg JC, Pattynama PM, Obermann WR, et al. Percutaneous computed tomography guided thermocoagulation for osteoid osteomas.Lancet 1995; 346:350-351.
PubMed
10) Lindner NJ, Ozaki T, Roedl R, et al. Percutaneous radiofrequency ablation in osteoid osteoma. J Bone Joint Surg 2001; 83:391-396.
 
11) Vanderschueren GM, Taminiau AH, Obermann, et al. Osteoid osteoma:clinical results with thermocoagulation. Radiology 2002; 224:82-86.
PubMed
12) Rosenthal DI, Hornicek FJ, Torriani M, et al. Osteoid osteoma:percutaneous treatment with radiofrequency energy. Radiology 2003; 229:171-175.
PubMed
13) Miyazaki M, Aoki J, Endo K, et al. Percutaneous Radiofrepuency Ablation for Osteoid Osteoma. J Intervent Radiol 2006; 21:271-275.
 
P.211 掲載の参考文献
1) 遠藤 拓ら:足趾変形したリウマチ足対応の靴の開発.靴の医学2006; 20:31-35.
 
2) 桃原茂樹ら:関節リウマチ患者における靴作製の留意点と工夫.靴の医学2005; 19:95-99.
 
3) 水落和也:関節リウマチの下肢装具療法, リハビリテーション医学2004:41:376-380.
 
4) 日本義肢装具学会:装具学【第3版】, 東京:医歯薬出版株式会社; 2003:63.
 
5) レネ・バウムガルトナーら:足と靴-その整形外科的処置法【改訂版】, 東京, フスウントシューインスティテュート:2002:124-128.
 

手術

P.217 掲載の参考文献
1) Banks SA, Harman MK, Hodge WA. Mechanism of anterior impingement damage in total knee arthroplasty. J Bone Joint Surg 2002; AM 84-A (Suppl 2):37-42.
 
2) Chiu YS, Chen WM, Huang CK, et al. Fracture of the polyethylene tibial post in a NexGen posterior-stabilized knee prosthesis. J Arthroplasty 2004; 19:1045-1049.
 
3) Stiel JB, Komistek RD, Dennis DA, et al. Fluoroscopic analysis of kinematics after posterior-crucitae-retaining knee arthroplasty. J Bone Surg Br 1995; 77-B:884.
 
4) Banks SA, Hodge WA. Accurate measurement of three-dimentional knee replacement kinematics using single-plane fluoroscopy. IEEE Trans Biomed Eng 1996:43:638.
 
5) Yamazaki T, Watanabe T, Nakajima Y, et al. Improvement of depth position in 2-D/3-D registration of knee implants using single-plane flouroscopy. IEEE Trans Med Imaging 2004; 2:602-612.
 
6) Watanabe T, Yamazaki T, Sugamoto K, et al. In vivo kinematics of mobile-bearing knee arthroplasty in deep knee bending motion. J Orthop Res 2004; 22:1044-1049.
 
7) Yamazaki T, Watanabe T, Nakajima Y, et al. Visualization of femorotibial contact in total knee arthroplasty using X-ray fluoroscopy. Eur J Radiol 2005; 53:84-89.
PubMed
8) Tamaki M, Tomita T, Yamazaki T, et al. The factors in high-flex posterior stabilized fixed-bearing total knee arthroplasty affecting in vivo kinematics and anterior tibial post impingement during gait.(Submitting)
 
9) Tamaki M, Tomita T, Yamazaki T, et al. In vivo kinematic analysis of a high-flexion posterior stabilized fixed-bearing knee prosthesis in deep knee bending motion. J Arthroplasty 2008; 23:879-885.
 
10) Tamaki M, Tomita T, Watanabe T, et al. In vivo kinematic analysis of a high-flexion, posterior-stabilized, mobile-bearing knee prosthesis in deep knee bending motion. J Arthroplasty 2009; 24:972-978.
 
11) Futai K, Tomita T, Yamazaki T, et al. In vivo kinematics of mobile-bearing total knee arthroplasty during deep knee bending under weight-bearing conditions. Knee Surg Sports Traumatol Arthrosc 2010 Sep 16.[Epub ahead of print]
 
12) Shimizu N, Tomita T, Yamazaki T, et al. The effect of weight-bearing condition on kinematics of a high-flexion, posterior stabilized knee prosthesis. J Arthroplasty 2011 Mar 22.[Epub ahead of print]
 
P.226 掲載の参考文献
1) McGirt AF, Parker SL, Wolinsky JP, et al. Vertebroplasty and kyphoplasty for the treatment of vertebral compression fractures:an evidenced-based review o the literature. Spine J 2009; 9:501-508.
 
2) Lieberman IH, Dudeney S, Reinhardt MK, et al. Initial outcome and efficacy of "Kyphoplasty" in the treatment of painful osteoporotic vertebral compression fractures. Spine 2001; 26:1631-1638.
PubMed
3) Wardlaw D, Cummings SR, Van Meirhaeghe J, et al. Efficacy and safety of balloon kyphoplsty compared with non-surgical care for vertebral compression fracture (FREE):a randomized controlled trial.Lancet2009; 373:1016-1024.
 
4) 戸川大輔.原発性骨粗鬆症性圧迫骨折に対するBalloon Kyphoplasty日本の臨床試験成績JSpine Res 2011; 2:1485-1493.
 
5) Kallmes DF, Comstock BA, Heagerty PJ, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures.N Engl J Med 2009; 361:569-579
 
6) Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures.N Engl J Med 2009; 361:557-568.
PubMed
7) Klazen CA, Venmans A, devries J, et al. Vertbroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II):an open-label randomised trail.Lancet 2010; 376:1085-1092
 
8) Edidin AA, Ong KL, Lau E,, et al. Ortality risk for operated and non-operated vertebral fracture patients in the Medicare population J Bone Miner Res 2011:10.1002/jbmr.353.
 
9) 武政龍一, 谷 俊一.骨粗鬆症性椎体骨折癒合不全に対するCPC椎体形成術の長所と短所 J. Spine Res2010; 1:1260-1266.
 
10) 武政龍一, リン酸カルシウムセメントによる椎体形成術.整形外科2011:62:703-712
 
11) 武政龍一.骨粗鬆症性椎体圧潰に対するCPC椎体形成術.馬場久敏 (編), OS Now Instruction No.18腰椎の手術ベーシックからアドバンスまで必須テクニック.東京; メジカルビュー社:2011; 140-146.
 
12) Patel AA, Vaccaro AR, Martyak GG, et al.Neurologic deficit following percutaneous vertebral augmentation. Spine2007; 32:1728-1734.
PubMed
13) 武政龍一.骨粗鬆症性椎体骨折の病態-骨折急性期から骨癒合不全および遅発性神経麻痺発症の病態まで.関節外科2010; 29:522-529.
 
14) Gold DT. The clinical impact of vertebral fractures:Quality of life in women with osteoporosis. Bone 1996; 18:185s-189s.
PubMed
15) Leidig-Bruckner G, Minne HW, Schlaich C, et al. Clinical grading of spinal osteoporosis:Quality of life components and spinal deformity in women with chronic low back pain and women with vertebral osteoporosis. J Bone Miner Res 1997; 12:663-675.
 
16) Leech JA, Dulberg C, Kellie S, et al. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 1990; 141:68-71.
PubMed
17) Gold DT. The nonskeletal consequences of osteoporotic fractures:Psychologic and social outcomes. Rheum Dis Clin North Am 2001; 27:255-262.
PubMed
18) Coelho R, Silva C, Maia A, et al. Bone mineral density and depression:A community study in women. J Psychosom Res1999; 46:29-35.
 
19) Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fracture. Am J Epidemiol 1993; 137:1001-1005.
PubMed
20) Silverman SL. The clinical consequences of vertebral compression fracture. Bone 1992:13 (Suppl 2) ; S27-31.
 
21) Kado DM, Lui L-Y, Ensrud KE, et al.Hyperkyphosis predicts mortality independent of vertebral osteoporosis in older women. Ann Intern Med 2009; 150:681-687.
PubMed
22) Suzuki N, Ogikubo O, Hansson T. The prognosis for pain, disability, activities of daily living and quality of life after an acute osteoporotic vertebral body fracture:its relation to fracture level, type of fracture and grade of fracture deformation. Eur Spine J 2009; 18:77-88.
PubMed
23) Nieuwenhuijse MJ, Van Erkel AR, Dijkstra S. Cementleakage in percutaneous vertebroplasty for osteoporotic compression fractures:identification of risk factors. Spine J 2011; 11:839-848.
 
24) 喜安克仁, 武政龍一, 谷 俊一ら.リン酸カルシウム骨セメントを用いた椎体形成術-治療成績と合併症.中部整災誌2006; 49:961-962.
 
25) Trout AT, Kallmes DF, Lane JI, et al. Subsequent vertebral fractures after vertebroplasty:association with intraosseous cleftd. AJNR Arn Neuroradiol 2006; 27:1586-1591.
 
P.237 掲載の参考文献
1) 荻野 浩.骨折とEBM-III.その他の骨折-.骨粗鬆症治療2004; 3:345-348.
 
2) Ruch DS. Fractures of the distal radius and ulna In Bucholz Rw, Heckman JD, Court-Brown CM, editors. Rockwood and Green's fractures in adults. Vol.1, 6th ed. Philadelphia:Lippincott Wilkins; 2006:909-964.
 
3) Sennwald G. The Wrist; Anatomical and pathophysiological approach to diagnosis and treatment. Berlin:Springer Verlag; 1987:115-154.
 
4) Hagino H, Yamamoto K, Ohshiro H, et al. Changing incidence of hip, distal radius, and proximal humerus fractures in Tottori Prefecture, Japan. Bone 1999; 24:265-270.
PubMed
5) Sakuma M, Endo N, Oinuma T, et al. Incidence and outcome of osteoporotic fractures in 2004 in Sado City, Niigata Prefecture, Japan. J Bone Miner Metab 2008; 26:373-378.
PubMed
6) Hove LM, Fjeldsgaard K, Reitan R, et al. Fractures of the distal radius in a Norwegian city. Scand J Plast Reconstr Hand Surg 1995; 29:263-267.
 
7) Kristbjorg S, Sigurdur H, Johann R. Epidemiology and treatment of distal radius fractures in Reykjavik, Iceland, in 2004. Comparison with an Icelandic study from 1985. Acta Orthopaedica 2011; 82:494-498.
 
8) Flinkkila T, Sirni? K, Hippi M, et al. Epidemiology and seasonal variation of distal radius fractures in Oulu, Finland. Osteoporos Int 2011; 22:2307-2312.
 
9) Wong PCN:Epidemiology of fractures of bones of the forearm in a Mixed South East Asan community, Singapore. Acta Orthop Scand 1965; 36:153-167.
 
10) Aoyagi K. Fall among community-dwelling elderly in Japan. J Bone Miner Res 1998; 13:1468-1474.
PubMed
11) 森谷浩治.橈骨遠位端骨折の疫学.斎藤英彦, 森谷浩治編.橈骨遠位端骨折-進歩と治療法の選択-, 初版.東京:金原出版:2010年:16-17.
 
12) 清水陽人. Colles骨折の嚆矢. Claude Pouteau.整形外科2002; 53:1229-1235.
 
13) Smith RW. A treatise on fractures in the vicinity of the joints and on certain forms of accidental and congenital dislocations.Hodges and Smith; 1847.
 
14) Smith RJ, Floyd WE III. Smith and Barton's fracture. In Barton NJ, editor. The hand and upper limb. Vol.4. Fracture of the hand and wrist. Edinburgh:Churchill Livingstone; 1988:252-266
 
15) 斎藤英彦.橈骨遠位端骨折の歴史的変遷.斎藤英彦, 森谷浩治編.橈骨遠位端骨折-進歩と治療法の選択-, 初版.東京:金原出版; 2010:1-3.
 
16) Muller ME, Nazarian S, Koch P, et al. The comprehensive classification of fractures of long bones. Berlin:Springer-Verlag; 1990:106-115.
 
17) Saito H. Classification of fractures at the distal end of the radius with reference to treatment of comminuted fractures. In Boswick JA, editor. Current concept in hand surgery. Philadelphia:Lea& Febiger:1983:129-145.
 
18) 斎藤英彦, 大滝長門, 田島達也.橈骨遠位端骨折.日手会誌1988; 5:942-948.
 
19) Melone CP. Articular fractures of the distal radius. Orthop Clin North Am 1984; 15:217-236.
PubMed
20) Cooney WP III, Linscheid RL, Dobyns JH. External pinfixation for unstable Colles' fractures, J Bone Joint Surg 1979; 61A:840-845.
 
21) 佐々木孝.橈骨下端骨折の観血療法のコツ (創外固定を含む). MB Orthop 1993; 6:53-63.
 
22) Salter RB, Harris WR. Injuries involving the epiphyseal plate. J Bone Joint Surg 1963; 45A:587-622.
 
23) 斎藤英彦.橈骨遠位端骨折の治療原則.斎藤英彦, 森谷浩治編.橈骨遠位端骨折-進歩と治療法の選択-, 初版.東京:金原出版; 2010年:91-99
 
24) Gupta A. The treatment of Colles' fracture. Immobilization with the wrist dorsiflexed. J Bone Joint Surg 1991; 73B:312-315.
 
25) 高畑智嗣.手関節背屈位ギプスを用いた橈骨遠位端骨折の治療.別冊整形外科2000; 37; 33-36.
 
26) 高畑智嗣.70歳以上の橈骨遠位端骨折に対する手関節背屈位ギプスの成績.日手会誌2005; 22:683-686.
 
27) 高畑智嗣.外傷に対するプライマリア (保存療法) ; 私はこうしている.橈骨遠位端骨折.整形外科プライマリケア.New Mook整形外科No.17.東京:金原出版; 2005:129-134.
 
28) Kapandji A.Losteosynthese per double embrochange intra-focal. Ann Chir 1976:30:903-908.
 
29) 佐々木孝.榛橈遠位端骨折の保存的治療-ギプス固定と創外固定の適応-.整・災外1989:32:249-256.
 
30) Clyburn TA. Dynamic external fixation for comminuted intra-articular fractures of the distal end of radius. J Bone Joint Surg Am 1987; 69:248-254.
PubMed
31) Pennig DW. Dynamic external fixation of distal radius fractures.Hand Clin 1993; 9:587-602.
PubMed
32) 田嶋 光, 藤原 明, 工藤修己ら.橈骨遠位端骨折に対するPinnig創外固定.日手会誌1995; 12:683-686.
 
33) Mc Queen MM. Redisplaced unstable fractures of the distal radius. J Bone Joint Surg 1998; 80-B:665-669.
 
34) 坂野裕昭.不安定型橈骨遠位端骨折に対するnon-bridging創外固定による治療.新OS Now手関節と肘関節-手術療法はどこまで進んだか.2004; 23:8-17.
 
35) 森田晃造.橈骨遠位端骨折治療用non-bridging type創外固定器の開発. 日手会誌2002:19:325-331.
 
36) 松村崇史, 吉田宏樹, 山部英行.橈骨遠位端骨折に対する閉鎖的non-bridging創外固定.各種骨折型に適合した遠位ピン刺入法.日手会誌2004; 21:176-180.
 
37) 越知健介, 高木岳彦, 別所祐貴ら.橈骨遠位端骨折に対するnon-bridging創外固定. Techno FIX 72例の検討とその適応.日手会誌20082008; 24:647-651.
 
38) 松村崇史.観血的治療法 (創外固定).斎藤英彦, 森谷浩治編.橈骨遠位端骨折-進歩と治療法の選択-, 初版, 東京:金原出版; 2010:163-167.
 
39) Axelrod TS, McMurtry RY. Open reduction and internal fixation of comminuted, intraarticular fractures of the distal radius. J Hand Surg 1990; 15A:1-11.
 
40) Peine R, Rikli DA, Hoffmann R, et al. Comparison of three different plating techniques for the dorsum of the distal radius. A biomechanical study. J Hand Surg 2000; 25-A:29-33.
 
41) Ring D, Jupiter JB, Brennwald J, et al. Prospective multicenter trial of a plate for dorsal fixation of distal radius fractures. J Hand Surg 1997; 22-A:777-784.
PubMed
42) Carter PR, Frederick HA, Laseter GF. Open reduction and internal fixation of unstable distal radius fractures with a low-profile plate; a multicenter study of 73 fractures. J Hand Surg 1998; 23A:300-307.
 
43) Rikli DA, Regazznoi P. Fractures of the distal end of the radius treated by internal fixation and early function:a preliminary report of 20 cases. J Bone Joint Surg 1996; 78B:588-592.
 
44) 本城 昌.背側プレート法 (double plating法) について. MB Orthop 2005; 18:37-47.
 
45) 本城 昌, 福田眞輔, 松末吉隆ら.橈骨遠位端関節内骨折に対する背側double plating法の治療.日手会誌2004; 21:485-490.
 
46) Orbay JL, Fernandez DL. Volar fixation for dorsally displaced fractures of the distal radius; a preliminary report. J Hand Surg 2002; 27A:205-215.
 
47) Kiyoshige Y. Condylar stabilizing technique for intra-articular fracrure of distal radius. Tech Hand Upper Extrem Surg 2005; 9:17-20.
 
48) Kiyoshige Y. Condylar stabilizing technique with AO/ASIF distal radius plate for Colles' fracture associated with osteoporosis. Tech Hand Upper Extrem Surg 2002; 6:205-208.
 
49) 清重佳郎.中高年女性橈骨遠位端骨折に対するcondylar stabilizing法.日整会誌1989; 63:245-261.
 
50) Valbuena SE, Cogswell LK, Baraziol R, et al. Rupture of flexor tendon following volar plate of distal radius fracture. Report of five cases. Chirugie de la main 2010; 29:109-113.
 
51) Benson EC, DeCavalho A, Mikola EA, et al. Two potential causes of EPL rupture after distal radius volar plate fixation. Clin Orthop 2006; 451:218-222.
PubMed
52) Orbay JL, Touhami A. Current concepts in volar fixed-angle fixation of unstable distal radius fractures. Clin Orthop 2006:445:58-67.
PubMed
53) Rikli DA, Jupiter JB Fragment-specific fixation of distal radius fractures using the 2.4mm Synthes locking system. A rationale for treatment 2006; Atlas Hand Clin 2006; 11:149-161.
 
54) Medoff RJ, Kopylov P.Immediate internal fixation and motion of comminuted distal radius fractures using a fragment specific fixation system. Orthop Trans 1998; 22:165.
 
55) Medoff RJ. Fragment-specific fixation of distal radius fractures. Atlas Hand Clin 2006; 11:163-174.
 

書評

最近チェックした商品履歴

Loading...